 |
|
|
| |
PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT
|
| |
| |
Reported by Jules Levin
The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC.
F Huang1, V Moschetti2, B Lang3, A Halabi4, M Petersen-Sylla4, C-L Yong1, M Elgadi51Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 4CRS Clinical Research Services Kiel GmbH, Lornsenstrasse, Kiel, Germany; 5Boehringer Ingelheim Ltd, Burlington, Ontario, Canada
|
| |
|
|
|
|
|
